3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

IMMUNOGENETICS AND IMMUNE RECONSTITUTION DURING POTENT ANTIRETROVIRAL THERAPY: NWCS 233, AN ANALYSIS OF AACTG PROTOCOL A5001

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. MoOa0303

Haas D.¹, Geraghty D.², Andersen J.³, DAquila R.¹, Unutmaz D.¹, Mar J.³, Benson C.⁴, Landay A.^5
1Vanderbilt University School of Medicine, Nashville, TN, United States of America, ²Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America, ³SDAC/Harvard School of Public Health, Boston, MA, United States of America, ⁴University of California at San Diego, San Diego, CA, United States of America, ⁵Rush Medical College, Chicago, IL, United States of America

INTRODUCTION: During potent antiretroviral therapy (ART) CD4 cell increases are modest in many patients. We explored whether single nucleotide polymorphisms (SNPs) in genes involved in T-cell expansion, survival, and apoptosis are associated with CD4 cell increases during ART.

METHODS: We studied previously ART-naïve subjects who had <400 plasma HIV-1 RNA copies/mL sustained for at least 48 weeks after initiating ART during Adult AIDS Clinical Trials Group (AACTG) trials. Eligible subjects participated in Protocol A5001, and contributed specimens to the AACTG Human DNA Repository via A5128. We characterized 137 SNPs in 17 genes by PCR-sequencing. Genes important for T-cell proliferation and survival encoded IL-15, IL-15 receptor α chain, IL-2/IL-15 receptor β chain, IL-2, IL-2 receptor common γ chain, IL-7, IL-7 receptor γ chain, TNF-α, IFN-α, and IFN-β. Genes important for T-cell apoptosis encoded TNF receptors I and II, FAS, FAS ligand, TRAIL, caspase 8, and BIM. The outcome variable was <200 CD4 cells/mm³ increase from baseline with 48 weeks of virologic control. There was no correction for multiple comparisons.

RESULTS: The 880 study subjects included 52% whites, 26% blacks, 20% Hispanics. 18% were female. 47% had CD4 change <200 cells/mm³. By univariate analyses, CD4 increases were associated with SNPs in genes encoding IL-15, IL-15 receptor α chain, IL-2/IL-15 receptor β chain, IL-7 receptor γ chain, TNF-α, TRAIL, and BIM (P<0.05 for each). In analyses that controlled for race, baseline CD4 count, viral load, HBsAg positivity, and sex, SNPs in genes encoding IL-15, IL-15 receptor α chain, TNF-α, TRAIL, and BIM were associated with CD4 rise at P<0.05.

CONCLUSIONS: Allelic variants in genes important for CD4 cell expansion, survival, and apoptosis may affect interindividual variability in immune reconstitution during ART. Characterizing these variants, variants in additional genes implicated in T-cell biology, and gene-gene interactions, may suggest novel interventions to enhance immune reconstitution.

Download PDF of this abstract.

050724
Basic | MoOa0303 | David Haas
16.7 118 16.7 Immune reconstitution

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.